Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02442817 · ClinicalTrials.gov registry record · Phase 4
Linagliptin and Mesenchymal Stem Cells: A Pilot Study
A Phase 4 study, sponsored by University of Nevada, Reno.
- Completed
- Registry status
- Phase 4
- Development phase
- 10
- Enrollment target
NCT02442817 is a Phase 4 study that has completed, run by University of Nevada, Reno. The registered enrollment target is 10 participants.
The verdict
NCT02442817, a Phase 4 study, has completed, sponsored by University of Nevada, Reno.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 10 participants
- Enrollment target
Study Summary
The purpose of the present study is to gather pilot data on the effects of linagliptin on the concentration of the long and short forms of SDF1-α (stromal cell-derived factor alpha) in humans, and to demonstrate the feasibility of such a study in patients with psychosis in our setting.
Interventions
- DRUG Linagliptin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2015-03-02 |
| Est. Completion | 2018-03-02 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02442817
The ClinicalTrials.gov registry entry for NCT02442817 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Nevada, Reno, which has 23 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Linagliptin is the first listed.
NCT02442817 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02442817 about?
NCT02442817 is a clinical study titled "Linagliptin and Mesenchymal Stem Cells: A Pilot Study". The purpose of the present study is to gather pilot data on the effects of linagliptin on the concentration of the long and short forms of SDF1-α (stromal cell-derived factor alpha) in humans, and to demonstrate the feasibility of such a study in patients with psychosis in our setting.
What is the current status of trial NCT02442817?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 10 participants. The study started on 2015-03-02. Estimated completion is 2018-03-02.
What interventions are being tested in trial NCT02442817?
The interventions under investigation include: Linagliptin (DRUG).
Who is sponsoring clinical trial NCT02442817?
This trial is sponsored by University of Nevada, Reno, which has 23 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.